کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5627209 1579668 2017 5 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Timing of anticoagulant re-initiation following intracerebral hemorrhage in mechanical heart valves: Survey of neurosurgeons and thrombosis experts
ترجمه فارسی عنوان
زمان شروع مجدد ضد انعقاد پس از خونریزی داخل مغزی در دریچه های قلب مکانیکی: بررسی کارشناسان عصبی و ترومبوز
موضوعات مرتبط
علوم زیستی و بیوفناوری علم عصب شناسی عصب شناسی
چکیده انگلیسی


- Intracranial hemorrhage (ICH) is the more feared complication of anticoagulation.
- Wide variation was noted in optimal timing for anticoagulant resumption post-ICH.
- Several hematoma, patient and valve factors influenced timing of resumption.
- High-quality data are urgently needed to improve clinical practice in this domain.

BackgroundWhile oral anticoagulation (OAC) is universally indicated for patients with mechanical heart valves (MHVs), OAC resumption following anticoagulant-associated intracerebral hemorrhage (ICH) is an area of uncertainty. We sought to determine the practice preferences of North American neurosurgeons and thrombosis experts on optimal timing of OAC re-initiation.MethodsA cross-sectional survey was disseminated to North American members of the American Association of Neurological Surgeons and the International Society for Thrombosis and Haemostasis. Demographic factors, as well as a clinical scenario with 14 modifiable clinical risk factors were included in the survey.Results504 physicians completed our survey (response rate 34.3%). Majority of participants were affiliated with academic centres, and managed ≤ 10 ICH patients with MHV per year. There was wide distribution in response in optimal timing for OAC resumption following an ICH: 59% and 60% preferred to re-start OAC between 3 and 14 days following the hemorrhagic event (median of 6-7 days). Smaller hemorrhages (<30 cm2). CHADS2 score ≥2, concomitant venous thromboembolism, mitral valve prosthesis, caged-ball valves and multiple valves prompted earlier OAC resumption.ConclusionWide variation in the current practice of neurosurgeons and thrombosis specialists exist when they encounter patients with ICH and MHV, though decisions were influenced by patient- and valve-related factors. As our observed variation likely reflects the immense gap in current evidence, prospective randomized trials in this population are therefore urgently needed.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Clinical Neurology and Neurosurgery - Volume 154, March 2017, Pages 23-27
نویسندگان
, , , , ,